These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 642716)

  • 1. Enhanced selectivity of pargyline as an inhibitor of type B monoamine oxidase in harmaline-treated rats.
    Fuller RW; Hemrick SK
    Life Sci; 1978 Mar; 22(12):1083-6. PubMed ID: 642716
    [No Abstract]   [Full Text] [Related]  

  • 2. MD 240928 and harmaline: opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice.
    Fuller RW; Wong CJ; Hemrick-Luecke SK
    Life Sci; 1986 Feb; 38(5):409-12. PubMed ID: 3945167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of harmaline on the ability of pargyline to alter catecholamine metabolism in rats.
    Fuller RW; Hemrick-Luecke SK; Perry KW
    Biochem Pharmacol; 1981 Jun; 30(11):1295-8. PubMed ID: 7271828
    [No Abstract]   [Full Text] [Related]  

  • 4. Depletion of epinephrine in rat hypothalamus by Ro 4-1284: influence of pargyline and harmaline.
    Fuller RW; Hemrick-Luecke SK
    Brain Res Bull; 1980; 5(5):589-91. PubMed ID: 6903452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Studies on monoamine oxidase. (Report 37) Effects of oxygen concentration on rat liver and brain monoamine oxidase (author's transl)].
    Nakagawa K
    Nihon Yakurigaku Zasshi; 1977 Apr; 73(3):297-305. PubMed ID: 21126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of substrate in the inhibition of rat liver and brain monoamine oxidase.
    Fuller RW
    Arch Int Pharmacodyn Ther; 1968 Jul; 174(1):32-7. PubMed ID: 4386711
    [No Abstract]   [Full Text] [Related]  

  • 7. A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)-amphetamine, p-methoxyamphetamine and harmaline.
    Green AL; El Hait MA
    Biochem Pharmacol; 1980 Oct; 29(20):2781-9. PubMed ID: 6893669
    [No Abstract]   [Full Text] [Related]  

  • 8. Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment.
    Waldmeier PC; Felner AE
    Biochem Pharmacol; 1978 Mar; 27(5):801-2. PubMed ID: 656120
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of monoamine oxidase by N-phenacyl-cyclopropylamine.
    Fuller RW; Hemrick SK; Mills J
    Biochem Pharmacol; 1978; 27(18):2255-61. PubMed ID: 728176
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical pharmacology of benzo(b)thiophene analogs of harmaline and harmine.
    Bosin TR; Campaigne E; Maickel RP
    Life Sci I; 1972 Jul; 11(14):685-91. PubMed ID: 4656100
    [No Abstract]   [Full Text] [Related]  

  • 11. Facilitatory and inhibitory effects of harmaline on the tryptophan-induced 5-hydroxytryptamine syndrome and body temperature changes in pargyline-pretreated rats.
    Abdel-Fattah AF; Matsumoto K; Murakami Y; El-Hady KA; Mohamed MF; Watanabe H
    Jpn J Pharmacol; 1996 Sep; 72(1):39-47. PubMed ID: 8902598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular turnover numbers of different forms of mitochondrial monoamine oxidase in rat.
    Egashira T; Ekstedt B; Kinemuchi H; Wiberg A; Oreland L
    Med Biol; 1976 Aug; 54(4):272-7. PubMed ID: 957813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective monoamine oxidase inhibitor drugs as aids in evaluating the role of type A and B enzymes.
    Fuentes JA; Neff NH
    Neuropharmacology; 1975 Nov; 14(11):819-25. PubMed ID: 1207877
    [No Abstract]   [Full Text] [Related]  

  • 14. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.
    Fowler CJ; Mantle TJ; Tipton KF
    Biochem Pharmacol; 1982 Nov; 31(22):3555-61. PubMed ID: 6817759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cumulative effects of irreversible MAO inhibitors in vivo.
    Felner AE; Waldmeier PC
    Biochem Pharmacol; 1979 Apr; 28(7):995-1002. PubMed ID: 444293
    [No Abstract]   [Full Text] [Related]  

  • 16. Some cardiovascular effects of monoamine oxidase inhibitors in unanaesthetized rats.
    Marwood JF; Huston V; Wall KT
    Clin Exp Pharmacol Physiol; 1985; 12(2):161-8. PubMed ID: 3839173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous peripheral leakage of pargyline on intracerebroventricular administration.
    Ali B; Parmar SS; Seth PK; Brumleve SJ
    Res Commun Chem Pathol Pharmacol; 1973 Nov; 6(3):1083-6. PubMed ID: 4760882
    [No Abstract]   [Full Text] [Related]  

  • 18. Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline- and harmaline-pretreated rats.
    Abdel-Fattah AF; Matsumoto K; Murakami Y; Adel-Khalek Gammaz H; Mohamed MF; Watanabe H
    Gen Pharmacol; 1997 Mar; 28(3):405-9. PubMed ID: 9068981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate-selective and tissue-selective inhibition of monoamine oxidase.
    Fuller RW; Roush BW
    Arch Int Pharmacodyn Ther; 1972 Aug; 198(2):270-6. PubMed ID: 5054735
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence for inhibition of monoamine oxidase in vivo in rat brain by 7,8-dichloro-1,2,3,4-tetrahydroisoquinoline.
    Fuller RW; Hemrick-Luecke SK
    Res Commun Chem Pathol Pharmacol; 1983 Mar; 39(3):519-22. PubMed ID: 6856953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.